纳米载体
纳米技术
纳米医学
脂质体
微流控
微泡
药物输送
细胞外小泡
小泡
胞外囊泡
纳米颗粒
固体脂质纳米粒
化学
靶向给药
材料科学
毒品携带者
膜
细胞生物学
生物
生物化学
基因
小RNA
作者
Masatoshi Maeki,Niko Kimura,Yusuke Sato,Hideyoshi Harashima,Manabu Tokeshi
标识
DOI:10.1016/j.addr.2018.03.008
摘要
Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100nm is attracting attention as a means to improve nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand, or electric charge or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs, and EVs and their applications for DDSs.
科研通智能强力驱动
Strongly Powered by AbleSci AI